Highest-materiality recent filing
Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026
Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.
Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M
Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.
Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.
Board approved 1-for-16 reverse split within previously authorized 1:5 to 1:30 range; effective 12:01 a.m. ET Dec 30, 2025.
Adicet Bio stockholders approve reverse stock split (1:5 to 1:30)
Proposal passed with 111,115,503 votes for, 2,752,862 against, and 117,502 abstentions.
Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.
Adicet Bio: 100% renal response in Phase 1 ADI-001 lupus nephritis; plans FDA meeting Q1 2026
Seven patients (5 LN, 2 SLE) dosed; follow-up 2–9 months as of Aug 31, 2025 cut-off.
Offering of 70,001,000 common shares at $1.00/share and pre-funded warrants for 10M shares at $0.9999 each.
Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%
Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.
Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026
Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.
Adicet Bio receives Nasdaq delisting notice for bid price below $1; cure period to Oct 6, 2025
Received Nasdaq notice on April 7, 2025 for non-compliance with minimum bid price rule (closing bid <$1 for 30 consecutive days).
Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25
Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.
Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC
ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.
First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.
Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001
Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.
Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications
Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.
Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome
FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.
Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1
Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.
Adicet prioritizes ADI-001 for autoimmunity; closes MCL enrollment; reports 80% ORR, 60% CR
Focuses ADI-001 development on four autoimmune indications: lupus nephritis, SLE, systemic sclerosis, ANCA vasculitis.
Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications
Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.
Adicet Bio receives FDA Fast Track Designation for ADI-270 in advanced kidney cancer
ADI-270 granted Fast Track Designation for metastatic/advanced clear cell RCC after checkpoint and VEGF inhibitor therapy.
ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.
Adicet Bio stockholders approve doubling authorized shares to 300M and 5M share plan increase
Authorized common shares increased from 150M to 300M via charter amendment; filed June 6.
Adicet Bio gets FDA Fast Track for ADI-001 in lupus nephritis; Phase 1 starts this month
FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III or IV lupus nephritis.
Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND
Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.
Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024
ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.
Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024
ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.
Net loss $29.5M ($0.69/share) in Q4 2023 vs $29.9M ($0.72/share) in Q4 2022; full-year net loss $142.7M ($3.31/share) vs $69.8M ($1.70/share).
On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.
On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.
Michael Kauffman, M.D., Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Nominating and Corporate Governance Committee (the “NCG Committee”), effective as of August 19, 2024.
the Board appointed Lloyd Klickstein, M.D., Ph.D. to the Board, effective as of August 19, 2024, to fill the vacancy on the Board.
Max materiality 0.85 · Median 0.60 · Most common event other_material